Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Elevated expression of FGF-2 does not cause prostate cancer progression inLNCaP cells
Autore:
Russell, PJ; Bennett, S; Joshua, A; Yu, Y; Dowing, SR; Hill, MA; Kingsley, EA; Mason, RS; Berry, J;
Indirizzi:
Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia Prince Wales Hosp Randwick NSW Australia 2031 ndwick, NSW 2031, Australia Univ New S Wales, Fac Med, Sydney, NSW, Australia Univ New S Wales SydneyNSW Australia s, Fac Med, Sydney, NSW, Australia Prince Wales Hosp, Dept Orthoped, Div Surg, Orthoped Res Lab, Randwick, NSW Prince Wales Hosp Randwick NSW Australia 2031 oped Res Lab, Randwick, NSW Univ New S Wales, Sch Anat, Cell Biol Lab, Sydney, NSW, Australia Univ NewS Wales Sydney NSW Australia l Biol Lab, Sydney, NSW, Australia Univtraliay, Dept Physiol, Vitamin D Bone & Skin Lab, Sydney, NSW 2006, Aus Univ Sydney Sydney NSW Australia 2006 e & Skin Lab, Sydney, NSW 2006, Aus
Titolo Testata:
PROSTATE
fascicolo: 1, volume: 40, anno: 1999,
pagine: 1 - 13
SICI:
0270-4137(19990615)40:1<1:EEOFDN>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
FIBROBLAST GROWTH-FACTOR; ANDROGEN-RECEPTOR GENE; FACTOR-ALPHA; LINE LNCAP; CARCINOMA; TUMOR; MUTATION; BENIGN; MODEL; BETA;
Keywords:
androgen-independent prostate cancer; growth factors; xenografts;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
63
Recensione:
Indirizzi per estratti:
Indirizzo: Russell, PJ Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia Prince Wales Hosp Randwick NSW Australia 2031 2031, Australia
Citazione:
P.J. Russell et al., "Elevated expression of FGF-2 does not cause prostate cancer progression inLNCaP cells", PROSTATE, 40(1), 1999, pp. 1-13

Abstract

BACKGROUND. Androgen-independent (AI) prostate cancer (CaP) resulting fromprogression of disease is untreatable. Such progression may relate to upregulation and autocrinicity of growth factor expression. We studied one candidate growth factor, basic fibroblast growth factor (FGF-2). METHODS. LNCaP cells made autocrine for FGF-2 by stable transfection with FGF-2 were examined for cancer progression, measured by 1) altered responseto androgen, 2) ability to grow more quickly when cocultured with bone cells in vitro or to form tumors when coinoculated with bone cells in vivo, or3) increase in metastatic ability. RESULTS. Stably transfected lines differed in FGF-2 protein expression. LNCaP-HF (high production of FGF-2) expressed more FGF-2 than LNCaP-LF (low production of FGF-2); controls were negative. In vitro, compared with LNCaPs, LNCaP-HF cells showed a slightly increased growth rate, reduced proliferation in response to androgen but not to estrogen or progesterone, and a decreased proliferative response to epidermal growth factor (EGF) and FGF-2. Although giving a slightly faster take rate, LNCaP-HF cells without Matrigelonly formed small, fast-regressing tumors in male nude mice, and with Matrigel, did not differ from LNCaPs in growth rate or tumor size. No metastases occurred. No tumors grew in females: Mixed growth of FGF-2 transfectants with human fetal osteoblasts failed to cross-stimulate in vitro, or to allow tumor formation in vivo. CONCLUSIONS. Although FGF-2 is overexpressed in AI CaPs, our experiments show that upregulation of FGF-2 expression is not sufficient to cause androgen independence, tumorigenicity, or metastases production (i.e., prostate cancer progression) in LNCaP cells. (C) 1999 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 18:28:08